Toronto, Ontario--(Newsfile Corp. - January 30, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading developer of needle-free devices to administer therapeutics subcutaneously, is pleased to announce that as of January 30th, 2024, Sol-Millennium Medical Inc.'s ("Sol-M") global sales & marketing team has now completed their in-depth clinical training of NuGen's needle-free InsuJet medical device for sales and marketing throughout Europe.
Louise Cresswell, NuGen's VP of Sales & Marketing for the UK and clinical expert, provided specialized training to a group of seven Sol-M sales representatives and equipped them with the necessary tools to employ a detail-oriented and proficient sales strategy for the European markets.
Training specifically included detailed instructions and hands-on training of NuGen's InsuJet needle-free device to facilitate sales as it pertains to the diabetic markets in France and Spain.
"Well-attended sessions with very good interactions from Sol-M sales representatives enabled me to share our experiences, and clinician and patient feedback of the InsuJetTM system to help the Sol-M team to drive sales and product adoption in their target markets throughout Europe," commented Louise Cresswell, NuGen's VP of Sales & Marketing. "The engagement and outcome with Sol-M were overwhelmingly positive with fulfillment set to achieve and perhaps even exceed expectations. I am very, very pleased," said Creswell.
As planned, European order forecasts are to be received by NuGen from Sol-M in the coming weeks which is in keeping with expectations with first orders arriving before the end of Q1 2024.
"In January this year, I personally met overseas with Liang Lin, CEO of Sol-M, and am pleased to report a very positive relationship that will continue to grow further. After in-depth sales, marketing, and promotion training with Sol-M, which took months to complete, we are delighted to now go to market with our co-branded InsuJet needle-free medical device and consumables," commented Ian Heynen, CEO. "As I stated earlier, 2024 will be a very busy year reporting commercial progress and wins in all three of our business verticals."
About Sol-M
Sol-M, NuGen's distributor since July 2023 for InsuJet in Canada, Brazil, France and Spain (See NuGen signs $204M distribution agreement with global leader in the diabetic industry) are global leaders in the healthcare industry with five offices around the world. Sol-M is a high-growth global medical device company committed to improving the safety and well-being of healthcare workers and their patients with the design and development of innovative safety-engineered medical devices. Sol-M is one of the world's largest designers and distributors of needles, syringes and diabetic supplies, offering a broad portfolio of patented products with global brand recognition such as Sol-Care for safety sharps, Sol-M for conventional medical devices and Sol-Guard for immunization products.
About NuGen:
NuGen is a leading developer of needle-free devices to administer therapeutics subcutaneously.
The Company is marketing and selling its next-generation InsuJet needle-free injection system designed to improve the lives of millions of diabetics.
InsuJet is approved for sale in 42 countries around the world.
For further information, please visit:
Websites: and
Instagram: @NuGenMD
Twitter: @NuGenMD
LinkedIn:
For further information, please contact:
Tony Di Benedetto
Executive Chairman
(416) 791-9399
tony@nugenmd.com
Ian Heynen
CEO
(416) 560-1019
ian@nugenmd.com
To arrange a media interview with NuGen, please contact:
Morna Gorman
(416) 553-1732
morna@nugenmd.com
Notice Regarding Forward-Looking Information:
Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accept responsibility for the adequacy or accuracy of this release.
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates, and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. These forward-looking statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. The forward-looking information contained herein is given as of the date hereof and the Company assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.
To view the source version of this press release, please visit
